-
NEJM and medRxiv: Two new studies show that people infected with the new coronavirus have a smaller risk of re-infection, but still need to be protected and not taken lightly
Time of Update: 2021-01-03
the results were published in the medRxiv preprint server and the NEJM journal under the titles "Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a developed risk of ion" and "Antibody Status and Agents of SARS-CoV-2 Infected in Health Care Care".
-
NATURE: IspH inhibitors are a two-pronged effort to kill Terrain-negative bacteria
Time of Update: 2021-01-02
, these IspH inhibitors can directly kill bacteria while activating the rapid immune response of cytotoxic gamma T cells, which may limit the increase in the population of antibiotic-resistant bacteria.
-
Chronic kidney disease-related itching (CKD-aP) breakthrough drug! Korsuva (difelikefalin), an opioid-infested (KOR) excitant, is on the market!
Time of Update: 2021-01-02
recently, the company announced that it had submitted a new drug application (NDA) for Korsuva (CR845, difelikefalin) injections to the U.S. Food and Drug Administration (FDA) to treat moderate to severe itching in patients with hemodialysis.
-
Scientific understanding of the prevalence of new coronavirus antibody in the population - a question and answer on the results of the national serological epidemiology of new coronary pneumonia
Time of Update: 2020-12-31
This new coronary pneumonia serological epidemiological survey is a month after China curbed the first wave of neo-crown pneumonia outbreak, in representative areas of the cross-sectional survey, through representative sampling in the population, serum samples collected for antibody testing, to understand the level of infection of the new coronavirus in the population.
-
Multiple articles explain how harmful smoking is to the body.
Time of Update: 2020-12-30
IJCP: The Effects of Smoking on Psoriasis Patients Doi:10.1111/ijcp.13751 According to a study published online October 14 in the International Journal of Clinical Practice, smoking has a negative effect on psoriasis, including increased incidence of nail injury and cardiovascular disease, as well as a higher psoriasis area and severity index.
-
Amiri's biosynthic drug RIABNI has been approved for listing by the FDA
Time of Update: 2020-12-30
On December 17th, Amgen announced that the U.S. Food and Drug Administration® (FDA) had approved the bio-similar drug RIABNI™ (Rituxan ®, Rituximab, Rituximab) Ritrituximab-arrx is listed in the United States for the treatment of adult non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), granuloma polymangiotisitis (GPA) (Wagner's granuloma) and microscopic multivascularitis (MPA).
-
Cell: Barrettinib reduces inflammation in rhesus monkeys infected with the new coronavirus
Time of Update: 2020-12-30
results were published online November 9, 2020 in the journal Cell under the title "Baricitinib treatment resolves lower airway macrophage and neutrophil search in SARS-CoV-2-infected rhesus macaques".
Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
-
Nature: Reveals the mechanisms by which chromosomal regulation leads to the production of diverse antibodies
Time of Update: 2020-12-30
in a new study, researchers from research institutions such as the National Institutes of Health (NIH), Boston Children's Hospital and Harvard Medical School found that not only our DNA, but also its structure and packaging, help us produce diverse antibodies.
-
The study revealed the molecular mechanism of herpes virus immune escape and host natural immune regulation
Time of Update: 2020-12-30
Recently, Deng Hongyu, a researcher at the Institute of Biophysics of the Chinese Academy of Sciences, identified a negatively regulated STING and MAVS-mediated natural immune response of the host protein phosphatase PPM1G, and analyzed the kaposi sarcoma-related herpes virus (KSHV) using the interstitrin ORF33 to hold PPM1G, the molecular mechanism of immune escape.
-
Mercadon acquires Oncolmmune: Obtains the first recombination fusion protein CD24Fc, Phase 3 clinical treatment COVID-19 has significant efficacy!
Time of Update: 2020-12-30
, Oncolmmune recently published positive results for the midterm efficacy analysis of COVID-19 Phase 3 clinical studies in CD24Fc, showing that CD24Fc has significant efficacy in treating patients with severe and critical COVID-19.
-
Sina Medicine Live Lesson 10 - Use precision medicine to develop the world's first innovative drug
Time of Update: 2020-12-30
Tational December 22nd, the 10th lesson of "New Zhihui" hits the pound, and Dr. Green, Executive Medical Director of Soyuan Biopharmaceuticals, will share with you "the world's first innovative drug to develop precision medicine" and look forward to your participation.
-
Meningococcal vaccine! EU Approved Sanofi Men Quadfi: The first all-liquid 4-price vaccine ≥ 12-month-olds!
Time of Update: 2020-12-30
Nov 23, 2020 // -- Sanofi (EC) has approved Meningococcal conjunctivation vaccine Men Quardfi for active immunization in people 12 months and older to prevent invasive meningococcal disease caused by meningococcal groups A, C, W and Y.
-
New Crown Outbreak: 59.53 million! Vaccines: AstraZeneta/Oxford UNIVERSITY AZD1222 is 60-90% efficient and supplies to the world without profit!
Time of Update: 2020-12-30
recently, AstraZeneca announced positive high-level results from mid-clinical trials in the United Kingdom and Brazil to evaluate the COVID-19 vaccine AZD1222.
data show that AZD1222 is very effective in preventing COVID-19 (primary endpoint) and no hospitalization or severe cases have been reported among subjects receiving the vaccine.
-
Respiratory syncytial virus (RSV) vaccine! GSK maternal vaccine enters Phase 3 clinical study: can quickly induce strong immunity!
Time of Update: 2020-12-30
RSV-related lower respiratory diseases (LRTI) have significant morbidity and mortality rates in infants under 6 months of age, with nearly half of paediatric hospitalizations (approximately 1.4 million cases) and deaths occurring in infants and young children under 6 months of age.
-
15-price pneumonia vaccine! Mercedon V114 filed for listing in the U.S. and the European Union: ≥ 18-year-old adult population!
Time of Update: 2020-12-30
the United States, 15 percent of adults 65 years and older with invasive pneumococcal disease are still caused by serotype 3; V114's Phase III clinical development project consists of 16 clinical trials that examine V1114's safety, tolerance, and immunogenicity in different populations, including healthy older people, healthy children, immunologically impaired people, and people with certain chronic diseases.
-
Nat Commun: Men have a three-fold higher risk of COVID-19 sepsis than women
Time of Update: 2020-12-29
men in intensive care units are three times more likely than women to die from the virus and 39 percent more likely to die from the virus, according to the study ( Photo: www.pixabay.com) data may help doctors recognize that gender is a risk factor for the severity of the disease when managing patients," said Kate Webb, co-author of the study.
-
Cell: The human body recovers from a mild new crown to maintain the new coronavirus-specific immune memory for at least 3 months
Time of Update: 2020-12-29
these recovered individuals produced SARS-CoV-2-specific IgG antibodies, neutral plasma, memory B cells, and memory T cells for at least three months.
Functional SARS-CoV-2-specific immune memory persists after mild COVID-19.
-
Sci Rep: The new method helps to find drugs to treat COVID-19
Time of Update: 2020-12-29
authors Vaibhav Srivastava and Arul Murugan say multi-targeting provides an effective way to respond to drug resistance, which will allow the drug to respond to mutations in the virus.
-
20 price pneumococcal vaccine! Pfizer 20vPnC receives FDA Priority Review: For ≥ 18-year-olds!
Time of Update: 2020-12-29
Dec 10, 2020 // -- Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has accepted a 20-price pneumococcal polysaccharide binding vaccine (20vPnC) The Biological Products Licensing Application (BLA) for PF-06482077 will be reviewed as a priority for the vaccine for adults 18 years and older to prevent invasive diseases and pneumonia caused by streptococcus pneumoniae serotypes in the vaccine.
-
Annals of Oncology: New guidelines for treating complications of brain cancer
Time of Update: 2020-12-29
(Photo: www.pixabay.com) "Every year, about 18 million people worldwide are diagnosed with cancer, and brain metastasis often occurs in patients with advanced tumors, especially in lung, breast or skin cancer.
